secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001193125-25-142745
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios shareholders elect two directors, approve 2.5M share plan increase and say-on-pay
--------------------------------------------------------------------------------

- Class III directors Jacqualyn A. Fouse and David Scadden elected with 45.96M and 46.20M votes for, respectively.
- Non-binding say-on-pay approved: 46.84M for, 3.02M against, 16,430 abstain.
- 2023 Stock Incentive Plan amendment approved: 31.68M for, 18.20M against (36.5% opposition), adding 2.5M authorized shares.
- Ratification of PricewaterhouseCoopers as auditor: 51.20M for, 136,734 against, 22,781 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312525142745/0001193125-25-142745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312525142745/d943981d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-142745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer